Aligos (ALGS) Q2 2026 earnings review
One-Time Lifeline Masks Surging Burn Rate
Aligos Therapeutics temporarily paused its cash bleed this quarter, but the underlying operational costs are accelerating rapidly. The company recognized $27.8M in revenue entirely driven by a licensing agreement with Amoytop. This one-time influx artificially reversed the net loss trend, bringing it down to just $1.5M from $23.0M sequentially. However, excluding this non-recurring capital, the financial picture is strained: R&D expenses surged 72% YoY to $24.1M as the Phase 2 B-SUPREME trial hit full enrollment. While the Amoytop deal provides a critical lifeline, management's guidance indicates the cash runway still only extends through Q4 2026. Aligos bought itself time, but the structural cash burn is accelerating.
🐂 Bull Case
The $25M upfront payment and subsequent $3M milestone from Amoytop validate the commercial viability of Aligos' HBV portfolio in Greater China, while providing non-dilutive capital.
The Phase 2 B-SUPREME study for pevifoscorvir sodium fully completed enrollment (131 HBeAg+, 114 HBeAg-), de-risking the clinical timeline toward the late-2027 topline data readout.
🐻 Bear Case
Even with the $28M infusion from Amoytop (upfront + milestone), the company only has sufficient cash to operate through Q4 2026. A highly dilutive capital raise is imminent.
Stripped of the one-time revenue, the core business is burning cash faster than ever. R&D costs are up 72% YoY, indicating Phase 2 clinical execution is incredibly expensive.
⚖️ Verdict: ⚪
Neutral. Management executed exactly the type of partnership needed to survive, securing $28M in near-term cash. However, with operating expenses accelerating to ~$30M per quarter, this capital merely plugs the leak temporarily. Until the company secures long-term funding or a buyout, the equity remains a high-risk waiting game.
Key Themes
Amoytop Partnership Execution
Strategic deal-making is acting as the primary financial driver. The exclusive license deal with Amoytop for pevifoscorvir sodium in Greater China delivered a $25M upfront payment, up to $420M in potential milestones, and tiered royalties. Furthermore, Amoytop's IND approval for ALG-170675 triggered another $3M milestone. This shift of regional R&D costs to a partner while extracting upfront cash is a critical survival mechanism.
Pevifoscorvir Sodium (CAM-E) Momentum
Clinical execution is stable and advancing. The Phase 2 B-SUPREME study fully completed enrollment across both HBeAg+ and HBeAg- cohorts. Furthermore, obtaining Breakthrough Therapy Designation from China's NMPA—on top of US FDA Fast Track Designation—accelerates the regulatory pathway for this potential best-in-class small molecule.
ALG-170675 ASO Innovation
Aligos is advancing its antisense oligonucleotide (ASO) technology through novel monomers designed specifically to reduce ASO toxicity and improve liver-to-kidney ratios. In vivo activity showed improved RNase H mediation over existing benchmarks like bepirovirsen. IND approval in China marks the transition of this innovative asset into the clinic.
Contradiction: Financial Position Weakness
Management stated they 'strengthened our financial position through non-dilutive capital.' However, the data contradicts this optimistic narrative. Total cash and investments stood at $30.4M at the end of Q2. Even adding the $25M upfront received in July ($55.4M pro-forma), the cash pile has significantly degraded from the $77.8M held just six months ago at the end of 2025. The cash burn is eating the fresh capital instantly.
R&D Expense Base is Accelerating
Research and development expenses are accelerating dramatically, hitting $24.1M in Q2 2026 compared to $14.0M in the same period last year (+72%). This margin compression is driven by third-party expenses for the Phase 2 B-SUPREME trial. As the trial progresses, there is no indication this elevated cost structure will reverse.
Silent on ALG-055009 (MASH) Asset
In prior quarters, management explicitly noted they were evaluating options to fund the development of their MASH candidate, ALG-055009. This quarter's release contains zero updates on out-licensing or funding for this program. The silence suggests a decelerating or stalled partnership process for an asset that previously generated positive Phase 2a data.
Macro Global HBV Burden
The macro backdrop remains a major structural tailwind. The World Health Organization estimates there are roughly 240 million patients globally suffering from chronic HBV, with 1.2 million new infections annually. Despite existing therapies, patients remain at high risk for liver cancer, framing the massive total addressable market if Aligos can successfully deliver a functional cure.
Other KPIs
Down sharply from $54.9 million in 26Q1 and $77.8 million at the end of FY25. Note: This figure strictly excludes the $25 million upfront payment from Amoytop received in July. Pro-forma cash including the payment sits near ~$55.4 million.
Stable sequentially compared to $29.76 million in 26Q1, but accelerating wildly YoY from $19.53 million in 25Q2 (+52%). The surge is almost entirely contained within the R&D segment, while G&A remains flat at $5.6 million.
Guidance
Stable. In Q1 2026, management guided that cash would last 'into the fourth quarter of 2026'. Despite bringing in $28M from Amoytop milestones and upfronts, the runway guidance barely changed, indicating the company's internal burn rate projections have increased to consume the new capital.
Stable. Aligos continues to point to late 2027 for the critical topline readout of both the HBeAg+ and HBeAg- cohorts, holding the line on clinical execution timelines following the completion of enrollment.
Key Questions
Bridging the Gap to Topline Data
Guidance indicates cash runway ends in Q4 2026, but the B-SUPREME Phase 2 topline data isn't due until late Q3 2027. Exactly how does management plan to finance the 9-month operational gap between running out of cash and delivering the catalyst data?
ALG-055009 Partnership Status
There was no mention of the MASH asset, ALG-055009, in this quarter's business progress. Has the strategy to out-license or secure external funding for this program stalled, and if so, is internal development completely paused?
R&D Expense Trajectory
With the B-SUPREME trial now fully enrolled, should we expect R&D expenses to plateau from the current $24M per quarter run-rate, or will ongoing patient monitoring costs keep expenses accelerating?